The European Medicines Agency has accepted for review marketing authorization applications (MAAs) for eight new drugs and has agreed to fast track its assessment for three of them.
The MAAs granted accelerated assessment are for Novimmune’s emapalumab*, for treating children with primary hemophagocytic lymphohistiocytosis (HLH), Theratechnologies/TaiMed Biologics’ multidrug resistant HIV treatment, Trogarzo (ibalizumab), and Loxo Oncology’s larotrectinib, for...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?